Neuropsychological Markers of Progression From Mild Cognitive Impairment to Alzheimer’s Disease

Marcos, Alberto; Gil, Pedro; Barabash, Ana; Rodríguez, R; Encinas, M.; Fernández, Cristina; Cabranes, José A.

doi:10.1177/1533317506289348

Cited by 29 publications

(30 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…clinics (39)(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52) and eight were population studies conducted in the community (53)(54)(55)(56)(57)(58)(59)(60). Sixteen were conducted using modified (non-Mayo) criteria.…”

Section: Search Resultsmentioning

confidence: 99%

Rate of progression of mild cognitive impairment to dementia – meta‐analysis of 41 robust inception cohort studies

Mitchell

Shiri-Feshki

2009

Acta Psychiatr Scand

1,358

932

View full text Add to dashboard Cite

Objective: To quantify the risk of developing dementia in those with mild cognitive impairment (MCI).Method: Meta‐analysis of inception cohort studies.Results: Forty‐one robust cohort studies were identified. To avoid heterogeneity clinical studies, population studies and clinical trials were analysed separately. Using Mayo defined MCI at baseline and adjusting for sample size, the cumulative proportion who progressed to dementia, to Alzheimer’s disease (AD) and to vascular dementia (VaD) was 39.2%, 33.6% and 6.2%, respectively in specialist settings and 21.9%, 28.9% and 5.2%, respectively in population studies. The adjusted annual conversion rate (ACR) from Mayo defined MCI to dementia, AD and VaD was 9.6%, 8.1% and 1.9%, respectively in specialist clinical settings and 4.9%, 6.8% and 1.6% in community studies. Figures from non‐Mayo defined MCI and clinical trials are also reported.Conclusion: The ACR is approximately 5–10% and most people with MCI will not progress to dementia even after 10 years of follow‐up.

show abstract

Section: Search Resultsmentioning

confidence: 99%

Rate of progression of mild cognitive impairment to dementia – meta‐analysis of 41 robust inception cohort studies

Mitchell

Shiri-Feshki

2009

Acta Psychiatr Scand

1,358

932

View full text Add to dashboard Cite

show abstract

“…Different neuropsychological assessment has been applied, in order to identify the most predictive tests in diagnosing early or pre-clinical AD [81,[83][84][85]. Notwithstanding, neuropsychological batteries alone did not reach exhaustive results.…”

Section: Combination Of Cerebrospinal Fluid Biomarkers: Abeta Peptidementioning

confidence: 99%

Combined Biomarkers for Early Alzheimer Disease Diagnosis

Borroni¹,

Premi²,

Luca³

et al. 2007

CMC

View full text Add to dashboard Cite

Few public health problems have captured the attention of the biomedical and lay communities alike as has Alzheimer Disease (AD). Several questions remain still open in disease management, as the necessity to delineate disease process from "normal ageing". In the last few years, Mild Cognitive Impairment (MCI) has received significant attention, thus it represents the major risk factor for AD. Not all people diagnosed as having MCI, however, will develop AD, hence there is a need to reliably predict progression. To this aim, different biomarkers have been proposed with the attempt to identify MCI people who already have pre-clinical AD. Neuropsychological assessment, peripheral and CSF biomarkers as well as neuroimaging findings (both structural and functional) have reported variable accuracy values, but better results have been obtained by combined biomarker approach. In this review, we summarise the most recent findings on combined biomarkers and their usefulness in clinical practice for the early and preclinical diagnosis of AD.

show abstract

“…Despite the great interest in identifying MCI patients who are at high risk for developing AD, presently there are no clinical or imaging markers that predict conversion to AD with certainty or reliably establish which MCI subjects will convert (Brayne, 2007; Marcos et al, 2006). While ongoing research emphasizes biological markers found in analyses of blood and cerebrospinal fluid (Bateman, Wen, Morris, & Holtzman, 2007; Papaliagkas, Anogianakis, Tsolaki, Koliakos, & Kimiskidis, 2009; Simonsen et al, 2007), in anatomical and functional brain imaging studies (Klunk et al, 2004), in event-related potential studies (Chapman et al, 2009; Chapman et al, 2007), and in other biomedical techniques, here we will investigate if behavioral markers measured through neuropsychological testing can be analyzed and combined in multivariate ways to predict conversion to AD.…”

mentioning

confidence: 99%

Predicting conversion from mild cognitive impairment to Alzheimer's disease using neuropsychological tests and multivariate methods

Chapman

Mapstone

McCrary

et al. 2010

Journal of Clinical and Experimental Neuropsychology

View full text Add to dashboard Cite

Behavioral markers measured through neuropsychological testing in Mild Cognitive Impairment (MCI) were analyzed and combined in multivariate ways to predict conversion to Alzheimer’s disease (AD) in a longitudinal study of 43 MCI patients. The test measures taken at a baseline evaluation were first reduced to underlying components (Principal Components Analysis, PCA) and then the component scores were used in discriminant analysis to classify MCI individuals as likely to convert or not. When empirically weighted and combined, episodic memory, speeded executive functioning, recognition memory (false and true positives), visuospatial memory processing speed, and visuospatial episodic memory were together strong predictors of conversion to AD. These multivariate combinations of the test measures achieved through the PCA were good, statistically significant predictors of MCI conversion to AD (84% accuracy, 86% sensitivity, and 83% specificity). Importantly, the posterior probabilities of group membership that accompanied the binary prediction for each participant indicated the confidence of the prediction. Most of the subjects (81%) were in the highly confident probability bins (0.70 – 1.00), where the obtained prediction accuracy was more than 90%. The strength and reliability of this multivariate prediction method were tested by cross-validation and randomized resampling.

show abstract

Neuropsychological Markers of Progression From Mild Cognitive Impairment to Alzheimer’s Disease

Cited by 29 publications

References 74 publications

Rate of progression of mild cognitive impairment to dementia – meta‐analysis of 41 robust inception cohort studies

Rate of progression of mild cognitive impairment to dementia – meta‐analysis of 41 robust inception cohort studies

Combined Biomarkers for Early Alzheimer Disease Diagnosis

Predicting conversion from mild cognitive impairment to Alzheimer's disease using neuropsychological tests and multivariate methods

Contact Info

Product

Resources

About